Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Coherus BioSciences is adding to its pipeline, this time grabbing commercialization rights for a biosimilar of one of the largest ophthalmology drugs on the market.
The biosimilars player said Monday that it is investing €30 million ($32 million) upfront to acquire the exclusive US commercialization rights for FYB203, a biosimilar of Regeneron’s blockbuster eye drug Eylea. Coherus bought the commercialization rights from Klinge Biopharma, which had in-licensed the candidate from Formycon, a German biosimilars developer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.